company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,187000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,187000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,187000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1690000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4814000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6504000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6317000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,82000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-67000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6384000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6384000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6384000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6384000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38540000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:23:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,170000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,170000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,170000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1690000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5657000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7347000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7177000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,67000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-40000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7217000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7217000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7217000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7217000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47576000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:07:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2223000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7993000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10216000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10151000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,22000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,40000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10133000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10133000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10133000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10133000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,59600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,59600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 16:12:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,56000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2436000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8896000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11332000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11276000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,30000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,26000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11250000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11250000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11250000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11250000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,59200000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,59200000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58938000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q2,2011-04-01,2011-06-30,2011-08-08 16:23:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,64000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,64000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,64000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1922000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8615000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10537000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10473000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,44000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,35000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10438000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10438000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10438000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10438000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,69600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,69600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,69725000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q3,2011-07-01,2011-09-30,2011-11-08 16:07:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,62000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,62000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2572000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9937000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12509000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12447000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,72000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,62000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12385000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12385000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12385000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,22000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12407000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,64100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,64100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,64248000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2489000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2489000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2489000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2739000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8942000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11681000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9192000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,51000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9141000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9141000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9141000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9141000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q1,2012-01-01,2012-03-31,2012-05-09 16:12:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2580000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8979000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11559000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11559000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,23000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,55000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,32000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11527000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11527000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11527000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11527000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,72000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,72000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71211000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q2,2012-04-01,2012-06-30,2012-08-08 16:11:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2647000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12641000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15288000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15288000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,49000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,33000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15255000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15255000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15255000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15255000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,76300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,76300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,74647000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q3,2012-07-01,2012-09-30,2013-11-12 16:29:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,118000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,118000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,118000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2935000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8437000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11372000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11254000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,50000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11204000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11204000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11204000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-39000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11165000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,73600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,73600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,73965000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3074000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8719000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11793000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11793000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,22000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,77000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,55000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11738000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11738000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11738000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11738000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,83800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,83800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,85850000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 15:58:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3545000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16568000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20113000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20113000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,185000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,173000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19940000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19940000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19940000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19940000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,95000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,95000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96580000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 16:01:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2734000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11342000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14076000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14076000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,166000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,157000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13919000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13919000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13919000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13919000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,99400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,99400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96648000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q3,2013-07-01,2013-09-30,2014-11-04 16:08:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3388000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10107000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13495000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13495000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,154000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,145000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13350000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13350000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13350000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,13000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13363000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,93600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,93600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,93983000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3393000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12842000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16235000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16235000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,158000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,147000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16088000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16088000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16088000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16088000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,94600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,94600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96792000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q1,2014-01-01,2014-03-31,2014-05-07 15:58:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3589000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12177000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15766000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15766000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,117000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,109000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15657000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15657000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15657000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15657000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,97900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,97900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,97017000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q2,2014-04-01,2014-06-30,2014-08-07 16:01:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3694000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12070000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15764000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15764000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,101000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,97000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15667000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15667000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15667000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15667000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,99031000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,99031000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,97900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:18:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5235000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21661000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21661000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,79000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,65000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21596000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21596000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21596000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,18000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21614000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,98600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,98600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,98367000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4243000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15156000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19399000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19399000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,152000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,136000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19263000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19263000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19263000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19263000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,113300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,113300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,111202000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 16:12:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,711000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,711000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,711000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10127000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19772000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29899000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29188000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,225000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,210000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-28978000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28978000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-28978000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-28978000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,115900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,115900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,117770000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:13:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33820000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33820000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,33820000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4856000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11983000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16839000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16981000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,346000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8944000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,9278000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,26259000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,26259000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,26259000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,26259000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,136439000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140024000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138200000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:18:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31591000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31591000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31591000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5450000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9642000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15092000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16499000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,465000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,453000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,16952000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,16952000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,16952000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,33000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,16919000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,126600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,126600000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,125592000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5440000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13278000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18718000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18718000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,679000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,664000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,138900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,138900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136640000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q1,2016-01-01,2016-03-31,2016-05-03 16:12:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5155000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14154000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19309000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19309000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,828000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,816000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18493000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18493000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18493000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18493000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,132100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,132100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136680000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 16:03:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4848000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16701000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21549000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21549000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,27000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,846000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,819000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20730000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20730000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20730000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20730000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,138200000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,138200000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136681000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 16:11:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15000000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7579000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12710000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20289000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5289000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,874000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,860000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4429000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4429000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4429000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4429000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,137100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,137100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136667000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5648000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15495000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21143000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21143000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,17000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1008000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,991000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20152000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20152000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20152000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20152000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,134300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,134300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136722000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q1,2017-01-01,2017-03-31,2017-05-04 16:45:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5363000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18253000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23616000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23616000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1085000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1073000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22543000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22543000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22543000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22543000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,140900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,136736000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 16:11:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4843000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15620000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20463000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20463000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1133000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1125000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19338000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19338000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19338000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19338000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,138100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,138100000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,137375000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:03:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10115000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14239000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24354000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24354000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1164000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1151000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23203000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23203000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23203000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23203000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,137500000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,137500000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,137180000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6016000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14049000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1750000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21815000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21815000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1239000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1227000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20588000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20588000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20588000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20588000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,137300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,137300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138014000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:03:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7463000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11023000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,75000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18561000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18561000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1370000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1362000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17199000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17199000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17199000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17199000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,143300000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:01:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4447000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12842000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,75000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17364000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17364000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1484000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1480000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15884000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15884000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15884000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15884000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,132400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,132400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138586000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 16:06:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5970000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12204000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18174000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18174000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1585000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1573000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16601000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16601000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16601000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16601000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,137800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,137800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138418000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5157000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14817000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,655000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20629000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20629000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1681000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1670000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18959000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18959000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18959000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18959000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,135400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,135400000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138716000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q1,2019-01-01,2019-03-31,2019-05-09 16:03:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5109000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15932000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21041000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21041000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1621000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1615000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19426000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,138800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,138800000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,138761000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:01:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6061000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14993000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21054000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1473000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1471000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19583000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19583000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19583000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19583000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,139900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,139900000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,139589000.0
Achillion Pharmaceuticals Inc,ACHN,,0001070336,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 16:06:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
